Login to Your Account



Gilead pipeline stumbles raise M&A din after 'mo' phase III trouble

By Marie Powers
News Editor

Thursday, November 17, 2016

Gilead Sciences Inc. reported another late-stage pipeline setback after a pair of phase III trials evaluating JAK inhibitor momelotinib (formerly GS-0387) in myelofibrosis missed key endpoints.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription